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Macrophages have emerged as a key component of the innate immune system that
emigrates to peripheral tissues during gestation and in the adult organism. Their complex
pathway to maturity, their unique plasticity and their various roles as effector and
regulatory cells during an immune response have been the focus of intense research.
A class of surface molecules, the G-Protein coupled receptors (GPCRs) play important
roles in many immune processes. They have drawn attention in regard to these functions
and the potential for therapeutic targets that can modulate the response of immune cells
in pathologies such as diabetes, atherosclerosis, and chronic inflammatory diseases.
Of the more than 800 GPCRs identified, ∼100 are currently targeted with drugs which
have had their activity investigated in vivo. Macrophages express a number of GPCRs
which have central roles during cell differentiation and in the regulation of their functions.
While some macrophage GPCRs such as chemokine receptors have been studied in
great detail, the roles of other receptors of this large family are still not well understood.
This review summarizes new insights into macrophage biology, differences of human,
and mouse macrophages and gives details of some of the GPCRs expressed by this
cell type.
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INTRODUCTION
Inflammation is a highly complex protective response of the mammalian immune system that is
initiated at sites of infection or injury. The main goal of this process is to remove the danger
stimulus and damaged cells, resolve inflammation, and support a repair of the damaged tissue.
However, if this process that is normally targeted at an infectious stimuli or injured tissue remains
unresolved, innate immune activation can be prolonged and become misdirected at healthy cells
leading to chronic inflammation and disease (1). Central to the inflammatory response and its
regulation is the cellular innate immune response that in its early stages encompasses an initial
neutrophil influx into the tissue followed by an immigration of monocytes and cells of the adaptive
immune system. Inflammatory monocytes differentiate and form a major cellular component, the
macrophages. Macrophages respond strongly and early to antigenic challenges in the tissue and the
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local cytokine environment. Their central role in the regulation of
an effective immune response is being increasingly appreciated
and their dysregulation in this early phase can lead to various
human diseases that are associated with chronic inflammation
(1). Thus, controlling macrophage-driven immune responses is
an important preventative and therapeutic goal in many chronic
inflammatory pathologies.
Macrophages have central roles in danger detection,
inflammation, and host defense (2). These innate immune
cells sense danger signals in their environment, inhibit or kill
pathogens, engulf apoptotic, and necrotic cells and present
antigens to adaptive immune cells (PMID:27313577). They
have evolved to detect various pathogen-associated molecular
patterns (PAMPs) and damage-associated molecular patterns
(DAMPs) in their environment and communicate with other
keys cells of the innate and adaptive immune system via an array
of cell surface receptors (3). For example, Toll-like receptors
(TLRs) are the most extensively studied pattern recognition
receptors that play crucial roles in regulating macrophage
biology and innate immunity (4). TLRs sense a variety of
extracellular and intracellular PAMPs and DAMPs and activation
of TLR-mediated cell signaling constitutes one of the earliest
response to danger detection in macrophages (4). Similar to
TLRs, a separate family of even more diverse sentinel cell-surface
receptors, the G-protein-Coupled Receptors (GPCRs) (5),
allows the cell to perceive and sense pathogen and damage-
associated danger signals integrating environmental signals with
cellular signaling networks. These GPCRs act as gate-keepers
in general and help in particular to shape immune responses
of macrophages toward extracellular pathogens as well injury
related danger molecules (6, 7). For example, the mammalian
immune system has evolved GPCRs as part of the complement
cascade that plays a critical, protective role in dealing with
microbial intruders (8). However, many mammalian pathogens
have developed innovate ways to escape being targeted by the
complement cascade through a range of different mechanisms
including the manipulation of macrophage GPCR signaling
(8, 9). Moreover, a large number of studies have demonstrated
clearly that mammalian GPCRs feature prominently in the
regulation of other aspects of macrophage biology including
macrophage development, differentiation and activation.
Understanding the key roles played by macrophage GPCRs
will help in designing effective therapies for a range of chronic
human inflammatory pathologies.
The human genome encodes more than 800 GPCRs that
bind to a large variety of endogenous ligands which control
many physiological processes and are major drug targets. Nearly
35 percent of all clinically used drugs target GPCRs (10).
Furthermore, many new GPCR-targeting drugs are currently
undergoing clinical trials in human patients or are in the last
stages of approval (10). With the recent emergence of three
dimensional crystal and cyro-electron microscopy structures
for several GPCRs (11), this family of cell surface receptors
promises many new opportunities for the development of new,
more effective therapeutic agents. Therefore, this review aims
to document current literature and present examples of how
GPCRs may play major roles in regulating various macrophage
functions in development, differentiation and activation. We will
also discuss examples of how targeting GPCR in macrophages
could potentially be harnessed for treating a wide variety of both
acute and chronic human inflammatory diseases.
NEW INSIGHTS IN MACROPHAGE
BIOLOGY
Macrophages together with monocytes comprise the
mononuclear phagocyte system (MPS) (12) [historically
named the reticuloendothelial system (13)] and are members
of the hematopoietic linage. Initially, it was assumed that
tissue macrophages originated from committed precursor cells
that differentiated in the bone marrow, entered the periphery
and replenished the various tissue specific populations by
immigration of circulating peripheral monocytic cells (12). A
specialized antigen presenting cell type termed dendritic cells
was added later to the MPS (14, 15). The increasing complexity
of the MPS and the interconnection of its various components
made it soon clear that the initial simplistic models required
updating. The historical development of the field of macrophage
research including the underlying experimental evidence and
the various iterations of the terminology has been detailed in a
recent review (16).
New technologies such as flow cytometry, confocal
microscopy, the genetic analysis of single cells, and fate
mapping by means of introducing dyes into the germ-line
of specific cell types have allowed major advances in our
understanding of MPS ontology. Our current understanding is
that during embryonic development, most tissues are seeded
by precursor cells in two waves that originate from yolk sac
and fetal liver, respectively. In the adult organism these tissue
resident macrophages propagate locally and largely remain in
homeostasis independently of a replenishment (17, 18). The
CNS-resident microglia (19) and skin-resident Langerhan’s cells
(20) are derived directly from yolk sac progenitors. These cells
are among the earliest immigrants in embryonic tissues (18) and
while microglial cells show hardly any turn over in adult tissues
the resident Langerhan’s dendritic cells of the skin are replaced
successively during adult life. Other tissue-resident macrophages
such as Kupffer cells (liver), alveolar macrophages (lung), and
skin macrophages are derived from fetal liver hematopoietic
cells and show a combination of proliferation and very limited
turnover under homeostasis (17). An exception is intestinal
macrophages which are originally derived from fetal liver but are
replaced soon after birth by bone marrow-derived monocytes
(21, 22). This process is microbiota driven and the influx is
maintained throughout adult life (23).
Committed Monocyte-DC precursors (MDP) are constantly
developing in the bone marrow (24) and replenish two mutually
exclusive lines of differentiation that lead to either monocytic
(25) or dendritic cell precursors (26, 27) both of which have
access to the periphery. Two chemokine receptors, CCR2, and
CX3CR1 are intimately connected with the development of
macrophages. Inflammatory as well as steady-state monocytes
leave the bone marrow as CD115+ CX3CR1
int Ly6Chigh
monocytes, guided by the chemokine receptor CCR2 (28).
Depending on the cytokine environment and the nature and
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kinetics of the acute inflammation, these cells can differentiate
into iNOS+ phagocytes as shown originally in the Listeria
monocytogenes model (29). Alternatively, these cells can
differentiate into inflammatory, monocytic DCs (moDCs) (30).
The regulation of these pathways has been attributed to an
intrinsic heterogeneity of the PU.1 expression of the initial
precursor cell population (31).
While steady state conditions favors a tissue-resident, self-
replicating macrophage compartment with minimal input from
the periphery, inflammatory conditions quickly result in a strong
influx of peripheral bone marrow (BM)-derived monocytes
which enter the tissue as inflammatory effector cells. Depending
on nature and kinetics of the specific inflammatory response
and the given cytokine environment, monocytes can rapidly
develop into inflammatory effector M1 macrophages producing,
in mouse and humans, molecules such as TNF and iNOS (32).
Alternatively, contradicting the notion that a differentiation to
tissue macrophages is a default pathway, they can recirculate
back to the lymph node (LN) with minimal differentiation
(33). While under certain circumstances they can take on
the appearance of the replaced tissue macrophages in some
tissues (e.g., liver) (34) these cells commonly fail to replace the
original tissue resident macrophages. After the elimination of the
inflammatory cues as the acute immune response retracts, the
majority of these cells die (35). A small proportion of monocyte-
derivedmacrophages which survive for reasons unknown display
remarkable plasticity and can differentiate directly to M2
macrophages (36). These macrophages express a different set
of effector molecules and have been described to be involved
in a different set of activities, such as tissue repair. While the
concept of a M1/M2 polarization was initially formulated to
explain differences in the way macrophages generated in vitro
responded to different stimuli it has now been widely accepted
that under physiological conditions in vivo, similar polarization
occurs (32, 37).
The heterogeneity of the local macrophage compartment and
the consequential complexity and integration of the various
cell populations has been highlighted in a detailed investigation
of the myeloid cells in the skin (38). Using two marker
molecules, CD64 and CCR2, five populations of macrophages
and dendritic cells with an array of different functions from
phagocytosis to antigen presentation have been identified (38).
This points to a major limitation of many current studies
based on an analysis of tissue samples. Only the analysis of
sorted cell populations or, preferably, single cell analysis of a
representative number of cells can resolve this heterogeneity.
A further caveat with regard to an analysis of monocytes of
macrophage populations in periphery or tissue is the plasticity
and responsiveness of the myeloid cells. Every analysis, especially
during an inflammatory response, has to be seen as a snapshot
of a transient situation (39). Within days, or even hours,
proportions populations and differentiation status may have
changed dramatically. A final reservation with regard to the
analysis of local macrophage populations is the ongoing lack
of an agreed set of marker molecules that allow to sufficiently
describe any given myeloid population in steady state and
inflammation (40).
HUMAN AND MOUSE MACROPHAGES:
HOW SIMILAR ARE THEY?
The question of the degree of similarity between the
inflammatory response in general and cells of the MPS in
particular in either mouse or human is only partly answered
and many aspects have not yet been elucidated (41). While
macrophage research in rodents is frequently based on either
thioglycolate-elicited peritoneal or bone marrow-derived
macrophages, in humans blood-derived monocytes are easily
harvested and therefore usually used for investigations after
cytokine-driven maturation (42). Nevertheless, there have
been some exceptions to this relatively common approach
and some progress in the alignment of these two systems has
been made. In a genetic approach, mouse and human blood
monocytes were isolated and cultured identically. This resulted
in a true comparison of conserved and non-conserved marker
molecules and showed, for example, that CD64 was elevated
as a surface marker on the comparable Ly6C+ mouse and
CD16− human monocyte populations. However, in contrast to
being weakly positive on mouse Ly6Clow monocytes, CD64 had
disappeared from human CD16+ monocytes. Other molecules
such as MHC class II were clearly differentially regulated in
both species with human monocytes uniformly positive for
this marker while mouse monocytes were almost entirely
negative without an activating stimulus (43). While this genetic
comparison allows precise delineations of gene expression, this
analysis neglects the functional aspect. Consequently, other
attempts to align various monocyte populations have relied
on comparative functional studies. Isolation and functional
analysis of CD14dim monocytes showed that they constituted a
homolog of the “patrolling” murine Ly6Clow monocyte subset
(44). Finally, an interesting approach to elucidate the role of
certain monocyte populations in humans is the analysis of
human inherited diseases such as autosomal dominant and
sporadic monocytopenia which results in an absence of myeloid
cells amongst others, in the periphery (45). A dissection of
the myeloid cell populations present or absent gave striking
insight in the ontology of the human MPS (46). Despite an
absence of peripheral monocytes, dermal macrophages and
Langerhan’s cells were not impacted by this disorder, as predicted
by mouse experiments.
STRUCTURE AND CLASSIFICATION OF
GPCRs
GPCRs are ligand-coupled proteins that are found in the
transmembrane region of the cell surface and function primarily
as transducers of extracellular stimuli into intracellular signals
that elicit cellular responses. In humans, over 800 GPCRs
have been identified in the genome (>3% of human genome)
and are associated with various ligands such as hormones,
neurotransmitters, growth factors, chemokines, ions, odorant
molecules, and even light photons (5). These ligands are
known to bind to only around 200–300 GPCRs, while the
remaining GPCRs are considered orphan receptors as no
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ligand or function has been identified so far. Many of the
remaining GPCRs are thought to be sensory in function
(47). GPCRs are central to various physiological functions
and dysregulated expression and signaling of GPCRs has
been associated with various chronic inflammatory diseases
such as rheumatoid arthritis (48) or diseases with certain
inflammatory aspects such as cancer (49, 50). This makes
GPCRs important targets for development of new therapeutics
and is reflected by over 35 percent of all clinically marketed
drugs designed and developed to modulate their function.
However, registered drugs have only been produced for
about 30–40 well-characterized GPCRs and therefore,
there are many opportunities to validate and discover
new drug targets and therapeutics from the remaining
GPCRs (10).
GPCRs have a common structure of seven transmembrane
α-helical segments (H1–H7) joined with three intracellular
(I1, I2, and I3) and three extracellular (E1, E2, and E3) loops,
an extracellular N-, and an intracellular C-terminus. The
crystallization and structural analysis of GPCRs including
rhodopsin, β1 adrenergic, β2 adrenergic, A2A adenosine,
glucagon, glucagon-like peptide, corticotropin-releasing
factor, metabotropic glutamate, and smoothen receptors has
provided new insights into the structure, mechanism, and
regulation of this class of receptors (11). Based on earlier
studies (51, 52) the International Union of Basic and Clinical
Pharmacology Committee on Receptor Nomenclature and
Drug Classification has categorized GPCRs into 5 different
families, which are class A (rhodopsin-like receptors), class B
(secretin-like receptors), class C (glutamate- like receptors),
frizzled, and other 7TM protiens (47). Class A also known
as rhodopsin-like receptors is the largest and most diverse
group amongst the five families and consists of receptors for
light, olfactory, biogenic amines, chemokines, prostanoids,
adrenaline, and many others. Class B includes receptors for
the parathyroid hormone, calcitonin and the diverse family
of gastrointestinal hormones such as glucagon and secretin.
Class C GPCRs consists of the GABAB receptor, calcium-
sensing receptor and the family of metabotropic glutamate
receptors. Class C is relatively small and members generally
contain a large extracellular amino terminus thought to
be important for ligand capture (47). Despite the general
sequence and structural similarities of members within
each family (over 25%), individual GPCRs have prominent
differences in their extracellular and intracellular loops and these
regions are important for ligand binding and interaction with
downstream mediators (53). These differences allow individual
GPCRs to exhibit unique signaling properties due to different
receptor couplings to different G proteins, resultant difference
intracellular pathway signaling, different G protein independent
pathway activation, as well as complex regulatory processes
such as receptor desensitization, internalization, endocytosis,
and re-sensitization (53). An updated list of human GPCRs
and their ligands has been provided by a committee of the
International Union of Pharmacology (47) and a frequently
updated webpage can be interrogated for the newest relevant
information (https://gpcrdb.org/).
OVERVIEW OF GPCRs-MEDIATED CELL
SIGNALING
The molecular structure, function and signaling of GPCRs have
been covered in detail before and will only be discussed briefly
(5, 11, 54, 55). Activation signals leading to a conformational
change in GPCRs causes the disassociation of a group of
proteins located at the cytoplasmic face of the plasma membrane
that receives, interprets and directs signals to diverse sets
of downstream target proteins. GPCRs are coupled to four
families of heterotrimeric αβγ guanine nucleotide-binding
proteins (G proteins) and ligand-induced dissociation of the
components triggers activation or inhibition of a range of
different intracellular effector systems (e.g., adenylate cyclase,
phospholipase C, phosphodiesterases, Ca2+mobilization, others)
that regulate cell function (5, 11, 54, 55). There are currently four
known distinct subfamilies of heterotrimeric Gα proteins (Gi/o,
Gs, Gq/11, and G12/13) (56) and activation and disassociation
of these proteins are the first step in the GPCR signaling
axis immediately downstream of activated receptors (5, 11,
54, 55). Activation of Gαi proteins inhibits adenylyl cyclase,
while Gαs activates adenylyl cyclase mediated cell signaling
pathways. Gαq activates phospholipase Cβ (PLCβ)-mediated
pathways and Gα12/13 that stimulate Rho guanine-nucleotide
exchange factors (5, 11, 54, 55). Activation of GPCRs by agonists
mediates an elusive conformational change to the receptor that
promotes the exchange of GDP for GTP in the α-subunit of
the associated G protein. This leads to the activation of the G
protein and the dissociation of its βγ dimer and α-subunit. Gβγ
subunits also regulate crucial signaling pathways and cellular
functions including effectors such as phosphatidylinositol-4,5-
bisphosphate 3-kinase (PI3K), and downstream AKT signaling
(11, 54, 55). G-protein signaling is terminated via receptor
desensitization and internalization. Desensitization of GPCRs is
initiated by phosphorylation of intracellular residues by GPCRs
kinases that induce recruitment and subsequent interactions with
other cytosolic β-arrestin proteins promoting internalization
(57–60). In some cases, internalized GPCRs may promote a
subsequent round of β-arrestin-mediated MAPK-ERK signaling
(57–60). Apart from internalization and signaling, β-arrestin
activation also regulates GPCRs trafficking and receptor recycling
(57–60). This diverse and interconnected cell signaling pathways
involved in GPCR-regulated biological responses definitely make
the discovery of new therapeutics a challenging and ever-
growing field. Nonetheless, a holistic understanding of GPCR cell
signaling pathways and the discovery of antagonists for some
of the GPCRs that have specific roles in driving inflammatory
responses in macrophages and other immune cells will hopefully
produce newer, more effective therapeutic agents for many
chronic inflammatory diseases.
MACROPHAGES AND GPCRs IN MURINE
AND HUMAN BIOLOGY
The putative roles of GPCRs in differentiating and mature
macrophages, and in steady state and inflammation have been
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TABLE 1 | GPCRs expressed on macrophages.
Full name Receptor abbreviation Class Function (macrophage) References
Sphingosine-1-phosphate receptor S1PR1 (EDG1), S1PR2 (EDG5)
and S1PR4 (EDG6)







Class A Macrophage activation (promotes M2) and
immune regulation
(67)
Chemokine receptors CR, CCR, CXCR, CX2CR,
CX3CR
Class A Cell migration during macrophage
development and inflammation, activation
(17, 29, 68)
Purinergic receptors P2Y purinoceptor family;
Adenosine or P1 receptor family
(ARA1-ARA3)
Class A Pro- and anti-inflammatory macrophage
activation
(69)
Complement protein 3a receptor C3aR Class A Innate immunity, metabolic regulation,
immune regulation
(70)
Complement protein 5a receptor C5aR Class A Macrophage activation (M1) and immune
regulation, migration.
(71–73)
Protease-activated receptors PAR1, PAR2, PAR3, PAR4 Class A Macrophage activation (M1) and immune
regulation
(74–76)
summarized previously (61). Since the publication of the above
study, the expression of GPCRs has been determined in human
primary monocytes and blood-derived macrophages in the
context of M1 vs. M2 polarization (62) or using GM-CSF
or CSF-1 as opposing cytokine stimuli (63). A comprehensive
experimental overview has addressed both aspects (7). Most
profiled GPCRs were downregulated after differentiation from
monocyte to macrophage but this study highlighted a set of
seven GPCRs with upregulated expression after this first step
and 15 GPCRs that were differently expressed after exposure
to different cytokine regimes without any further activation.
Finally, LPS activation identified further sets of GPCRs that
responded differently to this stimulus (7). Since this is the most
comprehensive study of regulation of GPCRs in macrophage
differentiation and inflammation we used it to guide us to
document emerging roles for GPCRs in regulating macrophage
biology (Table 1).
Sphingosine-1-Phosphate Receptor Family
Members S1PR1 (EDG1), S1PR2, and
S1PR4 (EDG6)
Members of the sphingosine-1-phosphate (S1P) receptor family
have been identified to have major roles in the immune
response. In a landmark study of the function of S1PR1
using a gene deficient mouse model and treatment with the
immunosuppressive drug FTY720 (a S1PR1 agonist which is
also known as fingolimod), it was demonstrated that S1PR1 was
involved in the regulation of T cell egress from the thymus
and lymphocyte egress from peripheral lymph nodes (77). The
lymphocyte retention in lymph nodes caused by FTY-720 led to
lymphopenia in the periphery. Further analysis showed that the
lympopena was only one effect of FTY-720. Treatment of mice
with the drug caused an accumulation of S1PR-positive CD68+
macrophages in the subcapsular sinus of mesenteric lymph
nodes which could be confirmed using flow cytometry while the
proportion of peripheral monocytes remained unchanged (78).
S1PR1 and a second sphingosine-1-phosphate receptor S1PR4
and are highly regulated duringmacrophage differentiation. Both
receptors showed an opposing regulation in CSF-1- vs. GM-
CSF-differentiated macrophages (7). FTY720 is phosphorylated
in vivo by sphingosine kinase and mimics sphingosine- 1-
phosphate (S1P) but is causing receptor internalization and
receptor downregulation (79). Thus, it can act as an agonist
for four of the five members of the S1P family of GPCRs.
Treatment of human microglia, monocyte-derived DCs and
macrophages with FTY720 affects the subpopulations differently.
It blocks a CD40L-induced IL-12p70 production by DCs and
macrophages but not microglia and increases IL-10 expression
exclusively in microglia. Therefore, it shifts the outcome of
macrophage polarization to an anti-inflammatory type (64).
Interestingly, an addition of the S1PR1-3 antagonist VPC44116
also blocked the expression of proinflammatory cytokines
confirming the important role S1PR1 has in anti-inflammatory
macrophage polarization (65). In EAE, the severity of clinical
disease was correlated with S1PR1 overexpression on myeloid
cells (80) while a downregulation of S1PR1 on astrocytes and
thus presumably non-immunological mechanisms of FTY720
were identified as contributing to a positive therapeutic effect
(81). Under the trade name Gilenya (Novartis) FTY720 has
been approved in 2011 for treatment of relapsing/remitting
MS. While S1PR2-deficiency does not have an impact on
expression of proinflammatory cytokines (65) it also causes
a significant accumulation of CD11b+ F4/80+ inflammatory
macrophages during experimental peritonitis indicating that S1P
acts as a negative regulator of macrophage infiltration (66).
Blocking of S1PR2 by genetic or pharmaceutical means in
an EAE model reduced the number of cells positive for the
microglia/macrophage marker ionized calcium binding adaptor
molecule 1 (Iba1), attenuated demyelination, and improved
clinical outcome (82). This result underlines the importance of
this second receptor in vivo.
Leucine-Rich Repeat-Containing G-protein
Coupled Receptor 4 (LGR4)
LGR4 is a Class A receptor (10) which together with the
related receptors LGR1−3 responds to proteins of the R-spondin
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family, a group of 4 secreted ligands that regulate the canonical
Wnt/beta-catenin signaling pathway (83). The expression pattern
of LGR4 in human tissues mapped by IHC analysis supports
a role in the development and maintenance of skin, kidney
and the reproductive systems (84). In comparison to monocytes
LGR4 was upregulated in both GM-CSF and CSF-1 stimulated
macrophages (7). A recent study has highlighted the role of
LGR4 in M2 polarization. The genetic targeting of this receptor
decreased the number of tumor-associated M2 macrophages
(TAM) together with reduced tumor growth in mouse tumor
models (67). This switch in macrophage polarization could result
in an exciting new therapeutic target that supports checkpoint
therapies in lung cancer such as anti-PD-1 therapy.
Chemokine Receptors
Chemokin receptors belong to the class A family of GPCRs
(10). A cluster of five chemokine receptors (CCR2, CCR5,
CCR7, CX3CR1, and FPR1) is strongly expressed on monocytes
(62). While most of these GPCRs are crucial for the guided
movement of cells of the immune system and are therefore of
pharmaceutical interest (68) especially two chemokine receptors,
CCR2 and CX3CR1 which contribute to monocyte emigration
from the bone marrow and support monocytes patrolling vessels,
respectively, is worth mentioning in the context of this review.
In particular the pro-inflammatory axis between CCL2 and
its cognate receptor CCR2 has been dissected in numerous
models and while in models of atherosclerosis andMS promising
results have been obtained other models have shown that there
numerous caveats and more work needs to be done to fully
understand the role of this receptor in inflammation. It could be
demonstrated that monocyte accumulation in the atherosclerotic
plaque is driven by different chemokine receptors such as CCR2
and CX3CR1 (85). Absence of CCR2 in a mouse model of
severe atherosclerosis reduced the formation of lesions (86).
Furthermore, a strong experimental case for an important role
of CCR2 (87) and CX3CR1 (88) was made in a model of
MS EAE using reporter mice that allowed an identification
of microglia and inflammatory monocytes and their functions
in the CNS (89). These reporter mice showed that microglia
expressed CX3CR1 from the embryonic stage to adulthood and
that the majority of inflammatory monocytes were CCR2+. In
both models an intervention in the CCL2-CCR2 axis seems to
be promising as a therapy and drugs are currently undergoing
clinical trials to determine their potential. However, in a mouse
model of Alzheimer CCR2-deficiency accelerate Alzheimer-like
symptoms in El Khoury et al. (90) and in a model of age-related
macular degeneration CCR2 and CCL2-deficient mice developed
increased symptoms of the disease (91).
Purinergic Receptors
Purinergic receptors consist of two families in the class A
subgroup of GPCRs that are nearly ubiquitously expressed at low
level and are activated either by Adenosine (P1 or Adenosine
receptors) or nucleotides (ATP, ADP, UTP, and UDP; P2Y
receptors). The family of P1 or adenosine receptors consists of
4 receptors (A1, A2A, A2B, and A3) encoded by separate genes
(92). Extracellular Adenosine is present in acute and chronic
inflammation and is used as a danger signal. Adenosine Receptor
A2A and A3 are especially interesting due to their ubiquitous
expression after cellular activation and their role in macrophage
polarization (69). Currently intensive research for antagonists is
ongoing with a special focus on cancer therapy (93, 94). P2Y
receptors are a subfamily of eight purinergic G-protein-coupled
receptors for adenosine and uridine nucleotides that belongs to
the Class A family (10). Receptors of this family are activated
by extracellular ATP and modify the inflammatory activation
of macrophages (69). P2Y purinoceptor 8 (P2RY8) was highly
enriched in macrophages after CSF-1 activation (7). A second
GPCRs of this family, P2ry12, has been identified as a signature
gene of homeostatic microglia (95). While other receptors of
this group have been targeted for drug development (1, 4, 11,
13, and 14), these receptors have not yet been explored as drug
targets (10).
Complement Protein 3a Receptor (C3aR)
The “Complement system” is an ancient and conserved
protein network of the immune system that is activated
through proteolytic cascades by serine proteases in a highly
coordinated and controlled fashion (70). Among complement
proteins, complement peptide C3a acts via an inflammatory
GPCR to trigger immune cell chemotaxis and/or inflammatory
responses (70). The complement peptide C3a is one of the
key chemoattractants and it specifically mediates chemotactic
effects by binding to the C3aR expressed on various immune
and non-immune cells such as monocytes, macrophages, mast
cells, eosinophils, stem cells, and many others. Furthermore,
in immune cells, treatment of C3a has been found to mediate
adhesion of eosinophils to cytokine-primed endothelial and
epithelial cells via integrin mediated interactions (96, 97).
Adhesion of leukocytes to endothelial cells is an important
step leading to diapedesis during cell migration. Apart from
cell adhesion, C3aR activation has also been found to mediate
chemotaxis of eosinophils and mast cells (98, 99). In some
immune cells, C3aR-mediated chemotaxis is regulated via the Gαi
signaling axis (100).
Although C3aR-mediated chemotaxis has been studied in
several types of cells, little is known about its effects on
chemotaxis and signal transduction in human macrophages.
To date, C3aR-mediated chemotaxis has only been studied in
the mouse macrophage cell line J774 (101). Various in vivo
mouse studies suggest that C3aR activation plays an important
role in inducing mouse macrophage infiltration and activation
to key metabolic organs such as adipose tissues and kidneys
(74, 102, 103). The analysis of C3aR-mediated chemotaxis and
inflammation in human monocytes and macrophages is of
increasing significance as previous studies have demonstrated
the involvement of both C3aR expression and macrophage
infiltration in various disease pathologies including arthritis,
bacterial meningitis, atherosclerosis, and diabetes (74, 102–106).
C3aR-mediated inflammatory responses have only been studied
in human monocytes (107) and C3aR activation has shown to
increase ATP eﬄux, NLRP3 inflammasome activation and IL1β
secretion in human monocytes (107). With the new discoveries
of potent and selective human C3aR agonists and antagonists,
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further studies on C3aR function in human macrophages will
provide important insights (108).
Complement Protein 5a Receptor (C5aR)
Cleavage of complement protein C5 produces complement
peptide C5a (70). Similar to C3a, complement peptide C5a is a
potent proinflammatory, and chemotactic factor that also acts
via an inflammatory GPCR to trigger immune cell activation
(71). The C5a receptor C5aR was recently renamed C5aR1
and is expressed widely on immune cells, including monocytes,
macrophages, eosinophils, neutrophils and T cells. Additionally
C5aR is expressed on non-hemopoietic cells in the liver, kidney,
adipose tissue, the central nervous system, and other tissues
(109). C5aR inhibition blocks inflammation in various mouse
models or can reverse established pathology in the K/B ×
N mouse arthritis model (72). Thus, therapeutic interventions
that target C5aR are currently investigated in diseases of
inflammatory etiology (110) as well as cancer (111).
Only a few potent and selective low molecular weight
peptidomimetic and small molecule C5aR antagonists have been
reported (73). These antagonists have shown anti-inflammatory
activity in vitro in human immune cells including macrophages
and efficacy in vivo in animal models of inflammatory
disease (73). C5aR antagonists 3D53, W54011, and JJ47
all show potent inhibition of C5a-induced chemotaxis and
inflammatory gene expression in human and rat macrophages
(73). Further C5aR has shown to differentially modulate LPS-
induced inflammatory responses in human monocytes and
macrophages (112). While C5aR activation potentiated LPS-
induced inflammatory mediators in human monocytes, C5a
inhibited these responses in human M1-like and M2-like
macrophages (112). Interestingly, C5aR activation also enhanced
clearance of the Gram-negative bacterial pathogen Salmonella
enterica serovar Typhimurium from human macrophages (112).
However, despite the importance of C5aR in macrophage biology
and the success in preclinical models of human inflammatory
diseases, few C5aR antagonists have so far progressed beyond
phase I clinical trials.
Protease-Activated Receptors
Protease activated receptors, PARs (PAR1-4), are an unusual
group of cell surface GPCRs, which self-activate after cleavage
of their N-termini by pre-dominantly danger-associated serine
proteases to enable coupling and activation of intracellular
G-protein signaling cascades (113). Among PARs, PAR2 is
the most highly expressed PAR on immune cells like human
macrophages and is activated by multiple proteases involved
in inflammation (74). Various extracellular pathogen-associated
(e.g., house dust mite and cockroach proteases, Gingipains,
and others) and damage-associated (thrombin, trypsin, tryptase,
tissue factor VIIa, kallikreins, neutrophil elastase, cathepsin G,
proteinase 3, and others), serine proteases are sensed by PAR2 to
trigger intracellular signaling and inflammation (74). In human
macrophages, PAR2 gene expression and cell-surface protein
expression are increased by LPS and common dietary fatty acids
such as palmitic, stearic, and myristic acids (74). PAR2 activation
is generally proinflammatory both in vitro and in vivo.
In vitro, PAR2 activation amplified palmitic acid-induced IL-
1β and IL-6 secretion from human M2-like macrophages and a
potent PAR2 antagonist GB88 prevented the augmented effect of
IL-1β and IL-6 secretion by PAR2 activation (74). Furthermore,
in both M1-like and M2-like human macrophages, the PAR2
activation increased TNFα and IL10 secretion in a manner
similar to LPS (114). Interestingly, human monocytes that were
matured to an M1 phenotype in the presence of a PAR2 agonist
had a reduced cell area, and released less TNF-α after LPS
challenge (75). In contrast, human monocytes matured to an M2
phenotype in the presence of a PAR2 agonist also had a reduced
cell area andmade significantly more TNFα after LPS stimulation
(75). Furthermore, a recent study suggests that PAR2 activation
promotes M1 macrophage polarization and inflammation via
activating the FOXO1 pathway in mouse macrophages (115). In
vivo, the PAR2-activating protease, tissue factor VIIa, acting via
PAR2 activates adipose tissue macrophages, and causes insulin
resistance and metabolic dysfunction in mice (76). In another
independent study, the PAR2 antagonist, GB88, given orally to
diet-induced obese rats also completely attenuated adipose tissue
inflammation and prevented increased infiltrated macrophages
into the adipose tissue (116). Taken together, these in vitro and
in vivo studies suggest that among PARs, PAR2 might play an
important role in macrophage differentiation and activation.
However, no PAR2-directed therapies have yet been devised




Histamine H4 Receptor (HRH4)
HRH4 is a Class A histamine receptor that was initially cloned
and characterized as a result of a databank search and found
to be localized in blood and peripheral lymphoid organs
(123). The receptor was shown to be expressed specifically
by natural killer cells and cells of the myeloid linage (124).
In macrophages, it is exclusively upregulated after in vitro
stimulation of cells with GM-CSF while monocytes and CSF-
1 differentiated macrophages are virtually negative for this
receptor (7). This observation that GM-CSF is required for
HRH4 expression was supported by the finding that dendritic
cells expressed this receptor after differentiation frommonocytes
using this cytokine in combination with IL-4 (125). The role
of histamine in inflammatory conditions such as allergies and
the expression on cells of the immune system have generated a
strong interest in HRH4 as a drug target. Recent studies have
demonstrated a strong anti-inflammatory function of HRH4
inhibitors in psoriasis and lung inflammation (117).
5-Hydroxytryptamine Receptor 2B (5-HT2B)
and 7 (5-HT7)
HTR are a receptor family for the neurotransmitter 5-
Hydroxytryptamine (serotonin) that belongs to the Class A
family of GPCRs (10). Two members of this family 5-HT2B
and 5-HT7 have been identified to be expressed strongly on M2
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TABLE 2 | Other macrophage-expressed GPCR.
Full name Receptor
abbreviation
Class Function (macrophage) References
Histamine H4 receptor HRH4 Class A Potentially macrophage activation (M2) and
immune regulation
(117)
5-Hydroxytryptamine receptor 2B or
serotonin receptor 2B
HTR2B Class A Potentially macrophage polarization (M2) (118)
EGF-like module-containing mucin-like
hormone receptor-like (EGF-TM7 family)
EMR3 Class B Potentially macrophage activation and immune
regulation
(119)
Angiotensin receptors AT1 – AT4 Class A Pro- and anti-flammatory macrophage
activation
(120, 121)
Succinate receptor 1 SUCNR1 Class A M2 polarization, metabolic response of obesity (122)
Mas-related GPCR MRGPCRF Class A Potentially inflammation (7)
Endothelin receptor ETA, B1, B2, C Class A Potentially macrophage polarization and
inflammation
(7)
Lysophosphatidic acid receptor LPA5 or GPR92 Class A Potentially macrophage activation and
inflammation
(7)
G protein-coupled receptor family C
type 5A
GPCR5A Class C Inflammation (7)
macrophages with both receptors skewing the differentiation to
the M2 activation state (118). In an independent study it could
be shown that 5-HT2B while weakly expressed on monocytes
and GM-CSF macrophages was strongly upregulated by CSF-1
stimulation (7). While a large number of small molecule agonists
and antagonists for these receptor family have been established
and have been tested in clinical trials, none have been identified
that target macrophages specifically.
EGF-Like Module-Containing Mucin-Like
Hormone Receptor-Like 3
EMR3 belongs to the EGF-TM7 family of receptors. All family
members are class B adhesion GPCRs (10) and expressed
exclusively on cells of the immune system (126). In humans
EMR3 is present on myeloid cells including CD16+ monocytes
(127) and strongly upregulated after GM-CSF differentiation (7).
While the expression of adhesion GPCRs has been demonstrated
on macrophages in atherosclerotic plaques and autoimmune
inflammatory pathologies such as MS no clear understanding of
their function has been published yet (119).
Angiotensin Receptor 1 and 2
The two extensively studied angiotensin receptors AT1 and AT2
and two less characterized receptors (AT3 and AT4) are class A
GPCRs that are activated by the octapeptide effector hormone
Angiotensin II (Ang2). They are best known for their role
in regulating blood pressure and are targeted clinically in the
treatment of hypertension (128). AT1 and AT2 are expressed on
activated monocytes/macrophages and Ang2 has been shown to
provide a powerful proinflammatory stimulus via AT1 (120). In
contrast, the specific activation of AT2 on LPS-activated human
monocytic cell lines provides an anti-inflammatory signal and
causes a downregulation of the expression of proinflammatory
cytokines such as TNF (121). Since macrophages and their
expression of cytokines have been shown to play an important,
yet not entirely understood role in hypertension these divergent
roles of the angiotensin receptors could potentially be used to
develop a highly specific therapy for this pathology (129).
Succinate Receptor 1
In a recent publication, compelling evidence has been presented
that the Succinate receptor 1 (SUCNR1) is involved in M2
polarization of adipose fat-associated macrophages. Thus, this
GPCR is part of the regulatory system that controls the metabolic
response to obesity (122).
Other GPCRs
The Class A receptors Mas-related GPCRs (MRGPCRsF),
endothelin receptor (EDNRB), Lysophosphatidic acid receptor
5 (LPA5 or GPR92) and G protein-coupled receptor family C
type 5A (GPCRs5A) are strongly expressed after macrophage
differentiation (7) but have not yet been studied in detail in the
context of macrophage function.
ROLES OF GPCRs IN TISSUE-RESIDENT
MACROPHAGES
A multitude of GPCRs with ligands active in macrophage
development and localization (chemokine receptors) and
inflammation (biogenic amines (Histamin), lipid mediators
(prostaglandins, prostanoids, leukotrienes, platelet-activating
factor), peptide hormones (Chemokines, C5a, anaphylatoxin)
have been described to be expressed on mouse and human
macrophages (6, 7, 61). The sheer number of GPCRs expressed
on macrophages and the large variety of tissue-resident
macrophage populations make a comprehensive review not
feasible. Therefore, we will focus on cardiac and tumor-associated
macrophages as examples for emerging therapeutic targets.
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Cardiac Macrophages
Cardiovascular disease is despite intensive research and new
treatment options the leading reason for mortality worldwide.
The role of macrophages in the maintenance of cardiovascular
health has not been fully appreciated and only recently the
contribution of the innate immune system has begun to become
better understood (130–133). In the healthy heart macrophages
of embryonic origin are maintained by local proliferation (134).
They contribute to tissue homeostasis and regeneration by
phagocytosis of dead cells and tissue repair, produce locally
a variety of factors such as cytokines and have been shown
to form connections to cardiomyocytes which allows them
to support electrical conduction within cardiac tissue (131,
132). This population co-exists with monocyte derived CCR2+
macrophages and fate analysis has demonstrated that these
monocyte-derived macrophages replace successively with age
macrophages of embryonic origin (135).
After an ischemic myocardial injury a large number of
monocytes egresses the spleen and infiltrates the cardiac
tissue (136). The release from the spleen reservoir is not
CCR2-dependent as demonstrated in CCR2-deficient mice but
monocyte accumulation in the myocardium is lacking in this
model (136). An interesting role has been shown for the
angiotensin receptor 1 (AGTR1) using Atgr1a−/− animals (136)
Atgr1a is present on activated monocytes (137, 138) and in gene-
deficient mice the egress from the spleen is rendered ineffective
and reduced significantly (136). Since the influx of monocytes has
to be carefully timed to be beneficial and to contribute to tissue
healing after infarction both receptors, CCR2 and AGTR1 could
be a therapeutic target.
Tumor Associated Macrophages (TAMs)
Solid tumors that have become detectable clinically have evaded
immune surveillance. This is astonishing given that up to 3% of
the tumor mass consists of TAMs. The underlying mechanisms
how the immune response is subverted are still not understood
entirely (49) but a study of renal cell carcinoma has shown a
negative correlation of TAMs and regulatory T cells with long
term survival (139). It a meta-analysis of various other cancers
such as breast, bladder, ovarian, oral and thyroid cancer it has
been confirmed that the density of TAMs in tumor tissue allows
a negative prognosis of the overall survival (140). In contrast,
a positive effect could be detected in patients with colorectal
cancer (140). In a small pilot study no significantly different
effect of M1 vs. M2 macrophages could be detected. Therefore,
the role of macrophage polarization in human TAMs remains
controversial (140).
These observations that demonstrate that the presence of
macrophages has a negative effect on the outcome of cancer are
consistent with earlier studies that showed that the chemokine
CCL2 which is expressed by tumor cells and stroma drives the
recruitment. TAMs express vascular endothelial growth factor
A in the tumor environment and facilitate extravasation of cells
from the tumor thus promoting metastasis (141). A blocking of
the CCL2/CCR2 axis using an anti-CCL2 agent in a mouse model
reduces the number of infiltrating monocytes by preventing
them from leaving the bone marrow and inhibits metastasis
significantly (141). This points a potential therapeutic approach
that could be used to prevent the spreading of metastatic
tumor cells to secondary tissues. An unexpected side effect of
this therapeutic approach became apparent when the treatment
of CCL2 was interrupted (142). This caused an enhanced
mobilization of cells from tumors and an increased the number
of metastases (142). Nevertheless, antibody-based biologicals
and small molecule inhibitors specific for CCR2 are currently
used in trials for cancer treatment and other anti-inflammatory
therapies (10). Instead of blocking TAM infiltration an alternative
approach is desirable that aims at specific macrophage functions
or activities that support tumor growth. An example would be
the presence of large quantities of extracellular adenosine in
tumors. These nucleotides have been demonstrated to modify
macrophage activation (143). Activation of macrophages in the
presence of adenosine which acts through the A2A receptor
results in the M2 phenotype causing in immunosuppression
(144). Use of inhibitors of purinergic receptors in combination
with checkpoint therapy could be a useful new approach to cancer
therapy (145).
CONCLUSION
The complexity of the possible functional interactions of these
monocyte/macrophage receptors with the micro- and macro-
environment is elevated by various factors. First, macrophages
are a highly heterogeneous family of cells that are able to respond
to changes in the tissue environment with remarkable plasticity
(146). While reductionistic in vitro approaches have been able
to form a picture of specific gene signatures of macrophage
populations after stimulation with opposing cytokines such as
GM-CSF and CSF-1 or IL-4 and IFN-γ (32, 36) it is highly
unlikely that under inflammatory conditions in vivo equivalent
populations can develop in adjacent tissue areas depending
on the respective conditions. In fact, recent, unbiased single
cell, deep sequencing experiments of microglia demonstrated an
impressive heterogeneity in the unchallenged brain and were
able to distinguish six different microglia populations (95). One
can speculate that in inflammation a similar approach would
show a vast and confusing number of macrophage populations
displaying different signatures due to concurrently ongoing
activation, differentiation and polarization.
Second, GPCRs e.g., LGR4 which are expressed on
macrophages show an overlapping expression in various
tissues such as skin and kidneys (84) while the expression
of other receptors e.g., EMR3 or CCR2 is limited to cells of
the hemopoietic linage. Receptors with an expression in the
myeloid line such as F4/80 (EGF-TM7 family) or CCR2 have
shown a specific non-overlapping function knockout studies in
mouse models (147, 148). How this translates to the function
of macrophages in a transient blocking in humans in vivo using
small molecule antagonists has not yet been experimentally
evaluated. Developing macrophage specific gene deficient mouse
models could be a first step to a better understanding of off-target
effects of an interference with specific receptors in complex
models such as infection.
Frontiers in Immunology | www.frontiersin.org 9 August 2019 | Volume 10 | Article 2031
Wang et al. The Immunomodulation Function of GPCRs in Macrophages
Finally, other complicating factors are tissue specific gene
regulation of GPCRs using different promoter structures (149)
and the possibility of an alternative splicing of these receptors
for example in the EGF-TM7 family of receptors resulting in
various final proteins (150). Overall, the broad range of these
receptors and the complexity of expression on macrophage
subsets may present challenges in effectively targeting them in
order to modulate macrophage activity for the treatment of
disorders involving these phagocytes. However, given that there
have been successes resulting in licensing of some agents, this
should be encouraging for further development and applications.
It is interesting to note that other small molecule targeted
therapies have shown unexpected but potentially useful off-
target effects. One example being abl kinase inhibitors for
chronic myeloid leukemia, such as Imatinib, having the ability
of inhibiting c-fms, the M-CSF/CSF-1 receptor, with inhibitory
effects on monocyte development, macrophage, and osteoclast
activity (151, 152). However, further work will be necessary to
unveil the full potential of a therapeutic targeting of GPCRs
on macrophages.
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